Regencell Bioscience Q1 2026 Earnings Results & Report

Regencell Bioscience EPS Results

• Actual EPS: -$0.0050
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Regencell Bioscience Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Regencell Bioscience (NASDAQ:RGC) is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.

The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions. Regencell has also conducted research involving formulations for other health conditions, but its principal strategic focus has been on treatments for dementia and ADHD. These products remain investigational and are subject to clinical development and applicable regulatory requirements.

Regencell was established in 2014 and is based in Hong Kong, where it conducts its research and development activities. The company is led by Yat-Gai Au, who serves as its chief executive officer and has been associated with Regencell’s development since its early operations. Regencell Bioscience Holdings Limited trades on the Nasdaq Capital Market under the symbol RGC.